These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32043907)

  • 1. Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
    Narayanan P; Curtis BR; Shen L; Schneider E; Tami JA; Paz S; Burel SA; Tai LJ; Machemer T; Kwoh TJ; Xia S; Shattil SJ; Witztum JL; Engelhardt JA; Henry SP; Monia BP; Hughes SG
    Nucleic Acid Ther; 2020 Apr; 30(2):94-103. PubMed ID: 32043907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
    Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
    Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
    Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
    J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
    Yarlas A; Lovley A; McCausland K; Brown D; Vera-Llonch M; Conceição I; Karam C; Khella S; Obici L; Waddington-Cruz M
    Neurol Ther; 2021 Dec; 10(2):865-886. PubMed ID: 34355354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 7. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
    Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
    Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
    Coelho T; Yarlas A; Waddington-Cruz M; White MK; Sikora Kessler A; Lovley A; Pollock M; Guthrie S; Ackermann EJ; Hughes SG; Karam C; Khella S; Gertz M; Merlini G; Obici L; Schmidt HH; Polydefkis M; Dyck PJB; Brannagan Iii TH; Conceição I; Benson MD; Berk JL
    J Neurol; 2020 Apr; 267(4):1070-1079. PubMed ID: 31853709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
    Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
    Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
    Karam C; Brown D; Yang M; Done N; Zhu JJ; Greatsinger A; Bozas A; Vera-Llonch M; Signorovitch J
    Muscle Nerve; 2022 Oct; 66(4):438-446. PubMed ID: 35799473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
    Benson MD; Dasgupta NR; Monia BP
    Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
    Coelho T; Marques W; Dasgupta NR; Chao CC; Parman Y; França MC; Guo YC; Wixner J; Ro LS; Calandra CR; Kowacs PA; Berk JL; Obici L; Barroso FA; Weiler M; Conceição I; Jung SW; Buchele G; Brambatti M; Chen J; Hughes SG; Schneider E; Viney NJ; Masri A; Gertz MR; Ando Y; Gillmore JD; Khella S; Dyck PJB; Waddington Cruz M;
    JAMA; 2023 Oct; 330(15):1448-1458. PubMed ID: 37768671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
    Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inotersen and severe thrombocytopenia: 2 case reports and review.
    Domínguez Senín L; Borrachero Garro C; Sánchez Gómez E; Santos-Rubio MD
    Int J Clin Pharmacol Ther; 2022 Jul; 60(7):311-316. PubMed ID: 35343431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotersen: First Global Approval.
    Keam SJ
    Drugs; 2018 Sep; 78(13):1371-1376. PubMed ID: 30120737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
    Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
    Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
    Dyck PJB; Kincaid JC; Wiesman JF; Polydefkis M; Litchy WJ; Mauermann ML; Ackermann EJ; Guthrie S; Pollock M; Jung SW; Baker BF; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):502-508. PubMed ID: 32654212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity Assessment of Inotersen, a 2'-
    Yu RZ; Wang Y; Norris DA; Kim TW; Narayanan P; Geary RS; Monia BP; Henry SP
    Nucleic Acid Ther; 2020 Oct; 30(5):265-275. PubMed ID: 32833564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
    Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
    Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
    Mahfouz M; Maruyama R; Yokota T
    Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.